TME Pharma

Glioblastoma Treatment with Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (GLORIA)
(ref: NCT04121455)
Status: active, not recruiting

Glioblastoma multiforme (GBM) is one of the deadliest and most aggressive forms of brain cancer. Patients with this devastating orphan disease are faced with extremely poor prognosis and a staggering 95% of them will not survive beyond 5 years. The standard of care – a combination treatment, including surgery, radiotherapy and chemotherapy – unfortunately is not curative. Moreover, not all patients benefit clinically from chemotherapy, which thus provides limited efficacy while increasing side-effect burden on patients. There is a huge unmet need for an effective approach to treat GBM that prevents tumor recurrence. Our approach is built on research and data suggesting that tumor microenvironment (TME) plays a critical role in how effective anti-cancer therapies are at fighting the disease.

GLORIA is Phase 1/2 study in glioblastoma (brain cancer) patients resistant to standard chemotherapy (unmethylated MGMT promoter) consisting of a dose-escalation part with NOX-A12 plus radiotherapy and three additional arms combining NOX-A12 with radiotherapy plus bevacizumab (VEGF inhibitor) or pembrolizumab (PD-1 inhibitor), or NOX-A12 plus radiotherapy in patients with complete tumor resection.

Therapies with NOX-A12 indicate promising and exciting efficacy, and potential for clinical benefit over standard of care.

Patients with Tumor Size
Patients with Partial Response
(>50% tumor reduction)
Standard of care historical control arm (n=20)1 25% 10%
NOX-A12 + RT
90% 40%
NOX-A12 + RT + BEV
100% 100%
(83% mRANO)

1. Giordano (2022) ASCO Annual Meeting Presentation #2050 link
2. Giordano (2022) SNO Annual Meeting Poster Presentation #CTNI-67 link & TME Pharma Press Release 19 November 2022 link
3. TME Pharma Press Release 28 June 2023 link
RT = Radiotherapy; Beva = bevacizumab. Standard of care = RT + chemotherapy

Results in NOX-A12 + RT + Bevacizumab combination generated and reported to date2,3:

  • 83% of patients (5 of 6) remain alive with a median follow-up of 15 months.
  • 100% of patients (6 of 6) attained radiographic partial responses (PR) of the tumor lesions (>50% shrinkage).
  • 83% of patients (5 of 6) achieved durable (>6 months) partial responses by mRANO criteria (modified Response Assessment in Neuro-Oncology), which takes into account radiographic response as well as other factors such as clinical condition of the patient.
  • 50% of patients (3 of 6) achieved >99% tumor size reduction incl. 1 complete response where the tumor disappeared completely and was no longer detectable by MRI
  • All mRANO partial responders maintained stable neurologic function as assessed by the NANO (Neurologic Assessment in Neuro-Oncology). Other quality of life measurements were stable or improved in the majority of patients with a median follow-up of 7.9 months.
  • The triple combination of NOX-A12, radiotherapy and bevacizumab was well tolerated and safe. No dose-limiting toxicities were observed.
We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.